Prostvac-VF: a vector-based vaccine targeting PSA in prostate cancer
- 24 June 2009
- journal article
- review article
- Published by Informa UK Limited in Expert Opinion on Investigational Drugs
- Vol. 18 (7), 1001-1011
- https://doi.org/10.1517/13543780902997928
Abstract
Prostvac is a prostate cancer vaccine regimen consisting of a recombinant vaccinia vector as a primary vaccination, followed by multiple booster vaccinations employing a recombinant fowlpox vector....Keywords
This publication has 106 references indexed in Scilit:
- Safety and Immunologic Response of a Viral Vaccine to Prostate-Specific Antigen in Combination with Radiation Therapy when Metronomic-Dose Interleukin 2 Is Used as an AdjuvantClinical Cancer Research, 2008
- Analysis of Overall Survival in Patients with Nonmetastatic Castration-Resistant Prostate Cancer Treated with Vaccine, Nilutamide, and Combination TherapyClinical Cancer Research, 2008
- Combination of Docetaxel and Recombinant Vaccine Enhances T-Cell Responses and Antitumor Activity: Effects of Docetaxel on Immune EnhancementClinical Cancer Research, 2008
- Cancer Statistics, 2008CA: A Cancer Journal for Clinicians, 2008
- Cancer Vaccines: Moving Beyond Current ParadigmsClinical Cancer Research, 2007
- Induction of Higher-Avidity Human CTLs by Vector-Mediated Enhanced Costimulation of Antigen-Presenting CellsClinical Cancer Research, 2005
- The Requirement of Multimodal Therapy (Vaccine, Local Tumor Radiation, and Reduction of Suppressor Cells) to Eliminate Established TumorsClinical Cancer Research, 2005
- T Cell Activation Pathways: B7, LFA-3, and ICAM-1 Shape Unique T Cell ProfilesCritical Reviews in Immunology, 1995
- Specific Immunotherapy Using a Recombinant Vaccinia Virus Expressing Human Carcinoembryonic AntigenAnnals of the New York Academy of Sciences, 1993
- Molecular cloning and sequence analysis of cDNA encoding human prostatic acid phosphataseFEBS Letters, 1988